Rhumatologie

No superiority of infliximab (INF) + methotrexate (MTX) over INF alone in the treatment of ankylosing spondylitis (AS): results of a one-year randomized prospective study

Poster – 69ème Congrès ACR – San Diego (Californie- USA) – 15-17/12/2005 Breban M, Ravaud P, Claudepierre P, Baron G, Hudry C, Euller Ziegler L, Pham T, Flipo RM, Chary-Valckenaere I, Marcelli C, Perdriger A, Le Loet X, Wendling D, Fautrel B, Fournie B, Combe B, Gaudin P, Saraux A, Mariette X, Baleydier A, Dougados M.

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France
Rhumatologie

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France

Cost utility modeling of early vs late total knee replacement in osteoarthritis patients.
Rhumatologie

Cost utility modeling of early vs late total knee replacement in osteoarthritis patients.

Predictive value of tender joints compared to synovitis for structural damage in rheumatoid arthritis
Rhumatologie

Predictive value of tender joints compared to synovitis for structural damage in rheumatoid arthritis